Navigation Links
Beckman Coulter Announces First Quarter 2008 Results
Date:4/30/2008

ded, "We are improving our full year outlook based on our first quarter performance. Assuming stable currency, full year revenue growth should be in the range of 11% to 13%. We expect 2008 operating income margin to be 12% to 12.5%. The outlook for non-operating expense is approximately $12 to $13 million per quarter. Pretax profit growth should be 12% to 15%, with a tax rate between 29% and 30%. We are raising the low end of our outlook for earnings per diluted share. Consequently, we expect our EPS to be between $3.55 and $3.65 based on a share count of 64.5 million. EBITDA for the full year 2008 should be $580 to $630 million. Capital expenditures are expected to be $290 to $310 million, and depreciation and amortization should be between $240 and $260 million.

"We're encouraged by the progress our company is making in 2008. We continue to significantly outperform the market in clinical diagnostics with strength in consultative selling, responsive service and innovative automation leadership. Clearly, we are making the improvements and investments necessary to achieve our revenue and earnings goals," he said.

Investor Conference Call

As previously announced, there will be a conference call today, Wednesday, April 30, 2008 at 8:30 am ET to discuss the first quarter ended March 31, 2008 results. The call will be webcast live and is accessible to all investors through Beckman Coulter's website at http://www.beckmancoulter.com or at http://www.streetevents.com. When accessing the webcast through the Beckman Coulter site, select "go to IR" under Investor Relations and find the call listed under "What's Ahead." The webcast will be archived on both websites for future on-demand replay through Friday, May 30, 2008.

About Beckman Coulter

Beckman Coulter, Inc., based in Fullerton, California, develops, manufactures and markets
'/>"/>

SOURCE Beckman Coulter, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23

Related biology technology :

1. Beckman Coulter Acquires Rights to Hepatitis C Virus
2. Beckman Coulter Declares Quarterly Dividend Payout of $0.17 Per Share
3. The Immune Tolerance Institute Announces Collaboration with Beckman Coulter Establishing a Multiplatform Immunophenotyping/Immunogenotyping Laboratory
4. Beckman Coulter to Present at the 2008 Bear Stearns London Healthcare Conference
5. Beckman Coulter Releases the High-Volume UniCel(R) DxC 880i Integrated Work Cell
6. AcroMetrix Signs Development and Supply Agreement With Beckman Coulter Inc. for Molecular Quality Control Standards
7. Beckman Coulter to Present at the JPMorgan Healthcare Conference
8. Beckman Coulter Elects AMN Healthcare Executive to Board of Directors
9. Beckman Coulter to Acquire Exclusive Rights to Break-Through Technologies
10. Beckman Coulter to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
11. Beckman Coulter to Present at the 19th Annual Piper Jaffray Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... -- The UPMC Center for Health Security today announced ... Leaders in Biosecurity Initiative (ELBI). As part of our ... biosecurity, UPMC has selected 28 US and international emerging ... including biological science, medicine, policy, the military, think tanks ... vision and support of the Defense Threat Reduction Agency ...
(Date:3/4/2015)... 4, 2015 /CNW/ - Resverlogix Corp. (TSX:RVX) (the ... a collaborative research program with Emerald Logic, ... Collective Evolution Technology (FACET), Emerald Logic analyzed ... obtained from each of 798 patients who ... trials ASSERT, SUSTAIN and ASSURE. The objective ...
(Date:3/4/2015)... SEOUL, South Korea , March 4, 2015 /PRNewswire/ ... based biopesticide company, in August of last year. As ... with Kyung Bon Koo continuing his role ... Selakovic , President of Vegalab S.A., will work alongside ... Photo - http://photos.prnewswire.com/prnh/20150303/179218 ...
(Date:3/3/2015)... 3, 2015 /PRNewswire/ - Aptose Biosciences Inc. (NASDAQ: APTO, ... molecular diagnostics that target the underlying mechanisms of cancer, ... period ended December 31, 2014. Effective July ... from May 31 to December 31. As a result ... are for the quarter and the seven months ended ...
Breaking Biology Technology:UPMC Center for Health Security Announces 2015 Emerging Leaders in Biosecurity 2UPMC Center for Health Security Announces 2015 Emerging Leaders in Biosecurity 3Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 2Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 3Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 4Korean Government Program Supports Vegalab's Research and Development 2Korean Government Program Supports Vegalab's Research and Development 3Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 2Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 3Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 4Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 5Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 6Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 7Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 8Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 9Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 10Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 11Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 12
... 12, 2011 Cord Blood America, Inc. ( www.cordblood-america.com ) ... company focused on bringing the life saving potential of stem ... is reducing the monthly payment in its unique "Afford-A-Cord" storage ... reduces the initial cost of storing umbilical cord blood stem ...
... 2011 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (NASDAQ: SSRX ... company focused on researching, developing, manufacturing and marketing biopharmaceutical ... first quarter ended March 31, 2011. ... Total net revenues increased by 22.7% ...
... 11, 2011 PharmAthene, Inc. (NYSE Amex: ... biological and chemical threats, today reported financial and operating results ... For the first quarter of 2011 PharmAthene recognized revenue ... period of 2010.  Revenues for the most recent quarter consisted ...
Cached Biology Technology:Cord Blood America Reduces "Afford-A-Cord" Program Charges; New Buyers Anticipated 23SBio Inc. Announces Unaudited First Quarter 2011 Results 23SBio Inc. Announces Unaudited First Quarter 2011 Results 33SBio Inc. Announces Unaudited First Quarter 2011 Results 43SBio Inc. Announces Unaudited First Quarter 2011 Results 53SBio Inc. Announces Unaudited First Quarter 2011 Results 63SBio Inc. Announces Unaudited First Quarter 2011 Results 73SBio Inc. Announces Unaudited First Quarter 2011 Results 83SBio Inc. Announces Unaudited First Quarter 2011 Results 93SBio Inc. Announces Unaudited First Quarter 2011 Results 103SBio Inc. Announces Unaudited First Quarter 2011 Results 113SBio Inc. Announces Unaudited First Quarter 2011 Results 123SBio Inc. Announces Unaudited First Quarter 2011 Results 13PharmAthene Reports First Quarter 2011 Financial and Operating Results 2PharmAthene Reports First Quarter 2011 Financial and Operating Results 3PharmAthene Reports First Quarter 2011 Financial and Operating Results 4PharmAthene Reports First Quarter 2011 Financial and Operating Results 5PharmAthene Reports First Quarter 2011 Financial and Operating Results 6
(Date:3/3/2015)... 3, 2015 Cryoport, Inc. (OTCBB: ... cryogenic logistics solutions for the life sciences ... cell lines, clinical research organizations, vaccine manufacturers, ... the expansion of its relationship with ... Hutch") Clinical Research Division with the inclusion ...
(Date:2/25/2015)... 2015  ABC Financial Services (ABC), the leading ... and Fitness Industry, today announced enhancements to their ... latest upgrade includes advances to the agreement section ... via Identity One fingerprint biometrics. The features will ... displays at the International Health, Racquet & Sportsclub ...
(Date:2/23/2015)... , Feb. 23, 2015 NXT-ID, Inc. ... the "Company"), a biometric authentication company focused on the ... filed provisional patent 62114357 for DISTRIBUTED VOICE ... patent, NXT-ID introduces a new groundbreaking payment method. Payment ... payment account may only be accessed if both the ...
Breaking Biology News(10 mins):Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 2Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 3ABC Financial Unveils New Software Enhancements 2ABC Financial Unveils New Software Enhancements 3NXT-ID Patents Voice Directed Payments 2NXT-ID Patents Voice Directed Payments 3
... German . Tomislav Domazet-Loo and Diethard Tautz from ... have systematically analysed the time of emergence for a large ... Their studies show for the first time that the majority ... of the first cells. The search for further genes, particularly ...
... cluster study The Australian Imaging, Biomarker and Lifestyle ... first collaborative research agreement with a major strategic alliance ... of its type, and aims to better understand the ... for early diagnosis. The study is an initiative ...
... tested at the National Institute of Standards and ... recent paper,* NIST scientists used surface-enhanced Raman spectroscopy ... qualities that make them superior for chemical and ... may one day be used in a range ...
Cached Biology News:Genetic based human diseases are an ancient evolutionary legacy 2Alzheimer's disease research attracts first partner 2Gold nanostars outshine the competition 2
... Adept CE 4100 high pressure pump ... precision, with software drive compensation, reducing pulsing ... are selectable in 0.001mL steps. , The ... and bio-compatible., Pumps may be programmed from ...
High affinity antibodies recognizes HSP70 protein from human cardiac tissue. Could be used for Westerb blotting application, ELISA....
Recommended for use as a cell culture substratum at 0.1-0.2 mg/cm 2 or 5-10 μl/cm 2 . Optimal concentration depends on cell type as well as the application or research objectives. Type B...
Monoclonal antibodies conjugated with rhodamine...
Biology Products: